Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 11 · inside the Ichimoku cloud · RSI 42 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.2M | 0.00% | 178.05K | +537% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ACHV trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 17, 2020 | Jacobs Cindy AOfficer | — | 69 | — |
| Aug 17, 2020 | Bencich John AChief Operating Officer | — | 69 | — |
| Aug 12, 2019 | Bencich John AChief Operating Officer | — | 1.4K | — |
| Jun 10, 2019 | Armistice Capital L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 2.53 - 3.38 per share. | 265K | $755.86K |
| Jun 10, 2019 | Armistice Capital L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 2.85 - 3.01 per share. | 47.2K | $134.82K |
| Jan 14, 2019 | Jacobs Cindy AOfficer | — | 42 | — |
| Jan 14, 2019 | Bencich John AChief Operating Officer | — | 28 | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.9 | 9.1 | -35.5 | 49.3 | 19.4 | 24.6 | -1.7 | 23.7 | 1.9 | -13.5 | +40.8% | ||
| 2025 | -7.1 | -6.1 | -13.0 | -2.6 | 37.7 | -36.9 | 15.5 | 14.2 | 5.7 | 62.5 | -4.9 | 2.1 | +41.2% |
| 2024 | 19.7 | -17.8 | 12.3 | -3.5 | 18.9 | -10.0 | 6.0 | -11.8 | 8.0 | -1.3 | -5.8 | -20.2 | −14.6% |
| 2023 | 98.4 | -0.2 | 40.2 | 22.5 | -25.6 | -16.3 | 7.9 | -11.4 | -13.3 | -6.5 | 44.0 | -28.8 | +68.2% |
| 2022 | -6.2 | 1.4 | 2.3 | -8.5 | -0.4 | -29.3 | 3.5 | -9.7 | -27.6 | -33.0 | 26.7 | -12.5 | −68.5% |
| 2021 | 50.6 | -6.4 | 1.4 | -6.8 | -25.8 | 12.1 | -18.6 | 14.2 | 1.8 | -2.5 | -13.1 | 8.1 | −4.0% |
| 2020 | 5.7 | -14.3 | -31.3 | 27.3 | -2.4 | -2.4 | 70.4 | -40.1 | 2.4 | -6.1 | 9.7 | -6.0 | −23.6% |
| 2019 | 24.0 | 63.3 | 31.8 | 31.6 | -0.9 | -54.2 | -5.2 | 8.7 | -14.6 | -24.1 | -28.7 | -42.4 | −56.2% |
| 2018 | 17.9 | -19.0 | -0.8 | 7.1 | -35.8 | -56.7 | -13.2 | -8.2 | 4.7 | -35.2 | -25.5 | -20.4 | −91.0% |
| 2017 | 12.0 | -1.8 | -20.0 | -13.6 | 0.0 | -5.3 | 19.4 | -25.8 | -42.2 | -14.8 | -23.1 | 0.8 | −75.6% |
| 2016 | -45.5 | -9.1 | 13.3 | 44.1 | 2.0 | 0.0 | -11.0 | -39.3 | -5.6 | -17.6 | 9.5 | 8.7 | −58.7% |
| 2015 | -12.2 | 14.4 | -6.5 | -6.5 | 5.5 | 9.9 | 48.1 | -15.7 | -23.4 | -7.2 | 24.6 | -53.1 | −47.2% |
| 2014 | 29.5 | 2.0 | 6.7 | -67.0 | -2.3 | -1.6 | -19.0 | 9.6 | -19.3 | -16.1 | -5.8 | 8.5 | −72.5% |
| 2013 | 0.3 | -9.7 | -4.7 | -10.6 | 1.7 | -4.9 | -0.3 | -8.4 | 3.6 | -24.2 | 22.2 | -2.9 | −36.4% |
| 2012 | 18.4 | 15.0 | -16.8 | -2.2 | -3.4 | 7.0 | 3.9 | -1.9 | 3.5 | -12.5 | 1.7 | 4.0 | +11.8% |
| 2011 | -5.6 | -0.9 | -2.5 | 1.4 | 12.9 | -2.7 | -15.1 | -17.4 | -17.9 | 18.4 | 2.8 | -1.5 | −30.1% |
| 2010 | -36.4 | 17.5 | 23.3 | 7.2 | -31.8 | -10.4 | 5.1 | -9.3 | 15.8 | 6.3 | 1.7 | 4.5 | −24.6% |
| 2009 | 47.7 | -14.9 | 21.2 | 45.5 | 165.4 | 24.0 | 33.4 | 37.6 | -10.4 | -19.1 | 8.3 | -29.4 | +642.7% |
| 2008 | -13.6 | 23.7 | -23.4 | 2.8 | -8.1 | -5.9 | -18.8 | 24.1 | -38.9 | -26.8 | -14.2 | 34.5 | −62.1% |
| 2007 | -6.4 | -6.1 | -6.3 | 10.1 | 3.6 | -8.0 | -5.3 | -13.6 | -85.6 | -16.1 | 11.5 | -24.1 | −92.8% |
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Buy / hold / sell counts